Clover Biopharmaceuticals

Executive Summary

Clover Biopharmaceuticals is a global clinical-stage biotechnology company based in Chengdu, China, focused on developing novel vaccines and biologic therapeutics for infectious diseases. The company gained international recognition for its COVID-19 vaccine candidate, SCB-2019, which utilizes its proprietary Trimer-Tag technology platform. This platform enables the production of stable, native-like protein subunit vaccines. Clover's initial commercial efforts have been challenged by the rapidly evolving pandemic landscape and intense competition, but the company has leveraged its expertise to build a diversified pipeline targeting other high-burden infectious diseases, including respiratory syncytial virus (RSV) and influenza. Clover's near-term prospects hinge on advancing its non-COVID pipeline and potentially securing regulatory approvals for its COVID vaccine in new markets. The company's RSV vaccine candidate is in early clinical development, and positive interim data could be a significant catalyst. Additionally, Clover may pursue partnerships to expand its manufacturing and distribution capabilities. However, the company faces financial pressure given its limited revenue stream and the need to fund ongoing R&D. Conviction in Clover is moderate, reflecting its promising technology but also execution risks in a competitive vaccine landscape.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Clinical Data for RSV Vaccine Candidate60% success
• Q2 2026China NMPA Approval or Emergency Use Authorization for Updated COVID-19 Vaccine70% success
• TBDStrategic Partnership for Vaccine Manufacturing or Distribution50% success